Advanced search
Publication Cover
Expert Review of Clinical Pharmacology Volume 14, 2021 - Issue 4
Submit an article Journal homepage
698
Views
10
CrossRef citations to date
0
Altmetric
Review

Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies

Zeng Wanga Department of Colorectal Pharmacy, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou, ChinaORCID Iconhttps://orcid.org/0000-0002-9414-1976View further author information
ORCID Icon,
Liyu Jiangb Center for Drug Safety Evaluation and Research of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, ChinaView further author information
,
Hao Yanb Center for Drug Safety Evaluation and Research of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, ChinaView further author information
,
Zhifei Xub Center for Drug Safety Evaluation and Research of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, ChinaORCID Iconhttps://orcid.org/0000-0002-1896-097XView further author information
ORCID Icon &
Peihua Luob Center for Drug Safety Evaluation and Research of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, ChinaCorrespondence[email protected] [email protected]
View further author information
Pages 445-456 | Received 20 Nov 2020, Accepted 19 Feb 2021, Published online: 28 Feb 2021

Citations (10)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Xiao-Yu Liu, Yong-Hong Wang, Jing Wang, Ji-Kun Quan, Xu-Dong Li & Kun-Ping Guan. (2023) The role of CSE1L silencing in the regulation of proliferation and apoptosis via the AMPK/mTOR signaling pathway in chronic myeloid leukemia. Hematology 28:1, pages 1-9.
Read now

Articles from other publishers (9)

Romeo G. Mihăilă. (2024) Advances in the Treatment of Chronic Myeloid Leukemia. Recent Patents on Anti-Cancer Drug Discovery 19:1, pages 1-17.
Crossref
Olga Mulas, Elisabetta Abruzzese, Luigiana Luciano, Alessandra Iurlo, Immacolata Attolico, Fausto Castagnetti, Sara Galimberti, Massimiliano Bonifacio, Mario Annunziata, Antonella Gozzini, Ester Maria Orlandi, Fabio Stagno, Gianni Binotto, Patrizia Pregno, Claudio Fozza, Maurizio Loi, Malgorzata Monika Trawinska, Fiorenza De Gregorio, Daniele Cattaneo, Francesco Albano, Miriam Iezza, Claudia Baratè, Luigi Scaffidi, Chiara Elena, Valentina Giai, Emilia Scalzulli, Massimo Breccia, Giorgio La Nasa & Giovanni Caocci. (2023) The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib. Annals of Hematology.
Crossref
Robert D. Schwab & Selina M. Luger. (2023) Which Second-Line Tyrosine Kinase Inhibitor(s) for Chronic Myeloid Leukemia?. Current Treatment Options in Oncology 24:7, pages 757-769.
Crossref
Jin-ping Liang, Rui-hua Mi, Lin Chen & Xu-dong Wei. (2023) Nilotinib cause moyamoya disease in the treatment of chronic myelogenous leukemia in chronic phase: A case report. Asian Journal of Surgery.
Crossref
Jayastu Senapati, Koji Sasaki, Ghayas C. Issa, Jeffrey H. Lipton, Jerald P. Radich, Elias Jabbour & Hagop M. Kantarjian. (2023) Management of chronic myeloid leukemia in 2023 – common ground and common sense. Blood Cancer Journal 13:1.
Crossref
Fang Cheng, Qiang Li, Zheng Cui, Mei Hong, Weiming Li & Yu Zhang. (2023) Dose optimization strategy of the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib for chronic myeloid leukemia: From clinical trials to real-life settings. Frontiers in Oncology 13.
Crossref
Jeffrey H. Lipton, Tim H. Brümmendorf, Carlo Gambacorti-Passerini, Valentin Garcia-Gutiérrez, Michael W. Deininger & Jorge E. Cortes. (2022) Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option. Blood Reviews 56, pages 100968.
Crossref
Monika Dudzisz-Śledź, Anna Klimczak, Elżbieta Bylina & Piotr Rutkowski. (2022) Treatment of Gastrointestinal Stromal Tumors (GISTs): A Focus on Younger Patients. Cancers 14:12, pages 2831.
Crossref
Yanli Zhang, Wendong Chen, Ashutosh Pathak, Yicheng Yang, Dajun Yang & Yifan Zhai. (2022) Burden of tyrosine kinase inhibitor failure in Chinese chronic myeloid leukemia patients: a systematic literature review. Journal of Comparative Effectiveness Research 11:8, pages 621-637.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.